A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2018
Price : $35 *
At a glance
- Drugs Afatinib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer
- Focus Therapeutic Use
- 12 Dec 2017 Planned End Date changed from 1 Jan 2020 to 1 Dec 2020.
- 12 Dec 2017 Status changed to active, no longer recruiting.
- 11 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.